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BRAIN tissue of rats pretreated with methylpredni-
solone or with the 21-aminosteroid U74389F, and
that of untreated control rats, was assessed for
the expression of annexin-1 (Anx-1) and the
transcription of its mRNA. For this purpose Anx-1
cDNA was amplified and simultaneously a T7-
RNA-polymerase promoter was incorporated into
the cDNA using a polymerase chain reaction
(PCR). Then digoxigenin-11-UTP was incorporated
into the transcribed cRNA with T7-RNA-polymer-
ase. With this probe in situ hybridization was
carried out on sections of the brain. The probe
was visualized by an immunoassay using an anti-
digoxigenin antibody conjugate. Anx-1 protein
was assessed by means of immunohistochemistry
using a polyclonal antibody. The various brain
areas of the control animals showed an appreci-
able amount of Anx-1 at mRNA or protein level;
on the other hand, the animals which had been
pretreated with either steroid, showed a more
intense Anx-1 mRNA signal than the controls in
many areas. In the pretreated animals A.-1
immunostaining was unchanged in cortex, basal
ganglia, amygdala and septum, but more intense
in hippocampus, hypothalamus and thalamus. In
ependyma, choroid plexus, meninges, and vascu-
lar walls there was no Anx-1 mRNA transcription
detectable. An opposite profile was shown by the
Anx-1 immunoreactivity, the protein was present
in control animals as well as the steroid-pre-
treated animals, suggesting that here the protein
was either from systemic origin, or has diffused
from adjacent structures. The results indicated
that Anx-1 mRNA transcription is upregulated by
either steroid, and that in the untreated animals
there is a resting level of Anx-1 mRNA transcrip-
tion, presumably reflecting physiological influ-
ences on Anx-1 expression.
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Introduction
Since the 1960s glucocorticoidsteroids have
been successfully employed in the clinical treat-
ment of vasogenic brain oedema. Oedema of
this type originates from disruption of the
blood-brain barrier, resulting in exudation of
blood plasma into the brain parenchyma. The
vasogenic oedema and the inherent disruption
of the blood-brain barrier tends to accompany
most focal lesions of the brain, such as tumours,
inflammatory lesions, infarctions, trauma and
haemorrhage. The disruption of the barrier
which is to be localized in the endothelium of
the cerebral capillaries, has been ascribed to
changes of endothelial permeability, allegedly
caused by oedema mediators, although the
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barrier defect in brain tumours is usually due to
the occurrence of fenestrations in the endothe-
lial cytoplasm.10edema mediators include free
unsaturated fatty acids, especially arachidonic
acid, and oxygen derived free radicals, which
have been shown to be produced in brain tissue
during injury. The unsaturated fatty acids are
released from membrane phospholipids by
phospholipase A2 attacking the glycerophos-
pholipid molecule at the sn-2 position. More-
over, arachidonic acid, and its derivatives the
eicosanoids, are allegedly involved in inflamma-
tory processes in other tissues of the body.
Annexins, or lipocortins, have been detected
as mediators of the anti-inflammatory action of
glucocorticosteroids by inhibiting phospholi-
pase A2 .2’3 This inhibition is both calcium-and
(C) 1996 Rapid Science PublishersInduction ofannexin-I
lipid-dependent.
4-6 Upon intravenous injection,
Anx-1, 2 and 5 proved to exert a potent anti-
inflammatory effect in rat and mouse.7’8 The
annexins are a family of proteins which all
possess a conserved 70 amino acid repeating
unit. In most annexins, there is a four-fold
repeat, except for Anx-6 which has eight such
repeats. Moreover, all annexins possess Ca2/
and phospholipid binding sites. The differences
between the annexin proteins are mainly lo-
cated in the amino-terminus.9
Anx-1 has been shown to be abundantly
present in extracts of human placenta, and in
the spleen, and kidneys of the rat. Readily
detectable tissue levels in the rat are found in
the lung, the thymus, the liver, the heart, the
brain, the bone marrow and the ileum. In a
previous immunocytochemical study on rat
brain, annexin-immunoreactivity only appeared
in sporadic microglial cells and in the choroid
plexus, being absent in the greater part of the
brain in animals not pretreated with steroids.
However, after administration of methylpredni-
solone or the 21-aminosteroid U74389F the
neurones, ependyma, oligodendroglia and capil-
lary endothelium of the brain showed an induc-
tion of annexin expression.
1
It has been the aim of the present investiga-
tion to assess in the central nervous system the
expression of Anx-1 by methylprednisolone and
the 21-aminosteroid U74389E mediated by the
transcription of Anx-1 mRNA, thereby excluding





The sequences of the oligonucleotides used in
this study and the predicted lengths of the PCR
amplification products are listed in Table 1. All
oligonucleotides were prepared at the BioMedi-
cal Technology Centre of the Academic Hospital
Groningen.
Polymerase chain reaction (PCR)
Circa 10ng annexin-1 (Anx-1) human cDNA
was used as PCR template. The use of human
cDNA is justified by the 87% homology with the
murine cDNA.
11 The PCR mixture consisted of
10 1 PCR buffer (500 mM KC1, 15 mM MgC12
and 100 mM Tris-HC1 pH 9.0), 1 nmol start and
stop primers, 10 1 dNTP mixture (2 mM dATE
dTTP, dGTP, dCTP) and sterile H20 to a final
volume of 100 1. After preheating the PCR
mixture for 5min at 94C, 2.5U Taq DNA
polymerase (Pharmacia Biotech, Uppsala, Swe-
den) was added. Then the mixture was covered
with 100 1 sterile paraffin oil. The PCR profile
was 94C for 1 min, 60C for 1 min and 72C for
1 min for 30 cycles in a thermal cycler (Pharma-
cia LKB Gene ATAQ Controller). Amplified DNA
was analysed by agarose gel electrophoresis and




All reactions involving the use of RNA were
performed with solutions treated with 0.1%
diethylpyrocarbonate (DEPC). Labelled cRNA
was produced with a T7-RNA-polymerase (Phar-
macia Biotech, Uppsala, Sweden) reaction to
which digoxigenin-ll-UTP (Boehringer Mann-
heim, Mannheim, Germany) was added. The
following reaction mixture was incubated at
37C for 2 h: 1/g PCR-product, 2/1 transcrip-
tion buffer (400 mM Tris-HC1 pH 8.0, 60 mM
MgC12, 20 mM spermidine and 100 mM NaCD,
2/.tl NTP-mixture (10 mM ATE CTP, GTP,
6.5 mM UTP and 3.5 mM digoxigenin-11-UTP),
63 U T7-RNA-polymerase and DEPC treated H20
to a final volume of 20 bl. The reaction was
arrested by the addition of 2 1 of 0.2 M EDTA
pH 8.0, followed by RNA extraction and pre-
Table 1. Sequences12of polymerase chain reaction primers (promoter sequence after
Young et al. (1993)
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cipitation. The transcripts were subjected to
agarose gel electrophoresis and Northern blot-
ting and identified by immunoassay using an
anti-digoxigenin antibody conjugate (Boehringer
Mannheim, Mannheim, Germany) following the
manufacturer’s instructions.
Steroids and dosage
Adult Wistar rats with a mean body weight of
350-400 g, which had free access to food and
water were used in the studies. They were
divided into three experimental groups: un-
treated control animals (n 7), a group treated
with 2 mg/kg methylprednisolone (Solumedrol,
UpJohn Co., Kalamazoo, USA) dissolved in
benzyl alcohol (n 8), and a group treated
with the 21-aminosteroid U74389F (UpJohn
Co., Kalamazoo, USA) dissolved in saline solu-
tion (n 4). All drugs were administered 24
and 2 h before the animals were killed. The
animals were anaesthetized with ether and
perfused with 0.9% NaC1 and 4% paraformalde-
hyde in 0.1 M phosphate buffered saline (PBS)
(pH 7.4). The brains were removed and cryo-
protected overnight in a 10% sucrose solution.
The brains were quickly frozen in CO2 and
sections of 40m thickness were cut on a
cryostat microtome. The sections were stored
in antifreeze (50% PBS, 30% ethylene glycol,
20% glycerol) at -20C. The sections were
mounted on poly-L-lysine coated slides, air dried
overnight and then used for in situ hybridiza-
tion (ISH).
In situ hybridization
The slides were incubated in a Proteinase K
solution (10 btg/ml in 10 mM Tris, 1 mM EDTA
pH 7.5) for 10 min at 37C, rinsed twice in PBS
and dehydrated in ethanol. On the slides 100 !,1
of hybridization mixture was applied. The
hybridization mixture consisted of 4*SSC
(I*SSC is 0.15M NaC1 and 0.015M sodium
citrate), l*Denhardt’s (0.02% Ficoll, 0.02% poly-
vinylpyrodilone, 10mg/ml BSA (Section V)),
50% deionized formamide, 5% dextran sulphate,
0.5 mg/ml tRNA and 1 bg/ml digoxigenin-la-
belled cRNA probe. The slides were covered
with coverslips and then sealed in a humid
plastic bag. Hybridization was conducted over-
night at 65C. Coverslips were removed with
4*SSC rinsing. Posthybridization washes were
as follows: 2*SSC, I*SSC, 0.5*SSC and 0.1*SSC
for 30 min at room temperature. To compare
the results in the various groups the ISH
procedure was carried out simultaneously for all
the groups.
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Immunological detection of
digoxigenin-labelled cRNA
The slides were rinsed in a solution containing
100 mM Tris and 150 mM NaC1 (pH 7.4) (buffer
1) for 1 min at room temperature and incubated
for 30 min in 1% blocking agent in buffer 1.
They were then washed for 1 min in buffer 1
and subsequently incubated with anti-digoxigen-
in alkaline phosphatase conjugated antibody
(1:500 diluted in buffer 1). The slides were
washed twice in buffer 1 for 15 min at room
temperature and equilibrated for 2min in
100 mM Tris, 100 mM NaC1, 50 mM MgC12 (pH
9.5) (buffer 2). The presence of the phospha-
tase on the slides was revealed with a fresh
colour substrate solution, containing 45 F1
90 mM nitro blue tetrazolium salt (NBT) (Sigma,
Bornem, Belgium) in 70% (v/v) dimethylforma-
mide, and 35 bfl, 120 mM 5-bromo-4-chloro-3-
indolylphosphate toludinium salt in 100% di-
methylformamide (BCIP) (Sigma, Bornem, Bel-
gium) in 10 ml of buffer 2. The reaction was
stopped in 10 mM Tris, 1 mM EDTA (pH 7.5).




Free-floating 40 bun thick sections of the brain
were washed three times with PBS and subse-
quently incubated overnight with a polyclonal
rabbit antibody raised against the amino termi-
nus of Anx-1.1 The antibody was diluted 1:40 in
PBS and the solution also contained 2% BSA and
10% normal goat serum. After three washes
with PBS the sections were incubated with the
secondary antibody (goat anti-rabbit 1:800)
(Sigma, Bornem, Belgium). After secondary
incubation, the sections were rinsed in PBS and
incubated in rabbit peroxidase anti-peroxidase
1:500 (Dakopatts, Denmark). Following the last
incubation, the sections were rinsed in PBS and
0.1 M sodium-acetate (pH 6.0). The reaction
was developed in 0.1 M sodium-acetate (pH 6.0)
containing 0.05% of the chromagen 3,3’-diami-
nobenzidine, 2.5% ammonium nickel sulphate,
0.4% ammonium chloride and 0.01% H202.
Staining was arrested by rinsing with 0.1 M
sodium-acetate (pH 6.0). After staining, the
sections were mounted on gelatin-chrom-alum-
coated slides, air-dried, dehydrated in a graded
ethanol series and xylol, and coverslipped with
DePeX (BDH, Dorset, UK). To allow comparison
of the various groups of animals, the immunocy-
tochemistry was carried out in the same session
to ensure similar reaction times. Moreover, theInduction ofannexin-1
tissue sections employed for immunohistochem-
ical detection of Anx-1 were adjacent to those
used for ISH of Anx-1 mRNA.
Analysis of results
The sections used in the ISH and immunocyto-
chemistry studies were analysed by two obser-
vers, who were unaware of the treatment of the
rats. The relative intensities of the hybridization
signal in the different brain regions were judged
as weak (/), strong (++), or very strong
(+++) (Tables 2 and 3). No attempt was made
to quantify the differences between the treated
animals and controls.
Results
Production of labelled cRNAs
By the inclusion of the T7-RNA-polymerase
promoter sequence in the 5’-termini of the PCR
primers (Table 1) the promoter was incorpo-
rated into the terminus of the Anx-1 cDNA
amplification products. Separate cDNA tem-
plates from which antisense and sense cDNAs
could be transcribed, were generated for the
Annexin-1 gene; and DNA fragments of the
predicted size could be demonstrated by restric-
tion and subsequent electrophoretic analysis of
the amplification products. Moreover, Northern
blot analysis showed discrete digoxigenin-con-
jugated sense and antisense cRNAs, which were
transcribed from the amplification products by
the T7-RNA-polymerase. The identities of the
cRNAs were confirmed using the template
cDNA and unlabelled cRNA as positive controls
to which the labelled Anx-1 cRNA specifically
hybridized.
In situ hybridization (ISH)
Using the digoxigenin-labelled antisense cRNA
probe for Anx-1 mRNA, in situ hybridization
(ISH) on paraformaldehyde-fixed frozen sections
of rat brains resulted in an adequate colour
reaction with minimal background staining.
Both the corresponding sense probe hybridiza-
tion experiment and the ISH, which had been
performed with the digoxigenin-labelled anti-
sense neo-RNA were negative, confirming the
specificity of the Anx-1 cRNA hybridization
reaction.
Table 2. Comparison between the subjective evaluations of Anx-1 mRNA ISH signal
distribution in control animals and animals treated with methylprednisolone or the
21-aminosteroid, and occurrence of glucocorticoid receptor (GR) immunoreactivity
Structure Control Methyl- 21-amino- GR-immuno
prednisolone steroid reactivity
Telencephalon
Caudate-putamen 4- 4-+ 4-4- +4-+
Cortex
Layer 0 0 0 0/+
Layer 2-6 + ++ ++ +++
Olfactory bulb + ++ ++ ++
Amygdala + ++ ++ ++
Corpus callosum
fibres 0 0 0
oligodendroglia + + +
Hippocampus
CA1 + +++ +++ +++
CA2 + +++ +++ +++
CA3 + +++ ++ ++
Dentate gyrus granular layer + +++ +++ +++
Fimbria hippocampi 0 0 0
Septum + ++ ++ ++
Bed nucleus striae terminalis + ++ ++ ++
Diencephalon
Hypothalamus + ++ ++ ++
Thalamus + ++ ++ ++
Epithalamus
habenular nucleus + +++ +++ +
Non-parenchymal tissue
Vascular wall 0 0 0
Meninges 0 0 0
Choroid plexus 0 0 0
Ventricular ependymocytes 0 0 0
The scores of subjective evaluations were ranked as follows: 0= no signal/cells labelled,
4- weak signal, +4- strong signal, 4-++ very strong signal.
aReference: Cintra et al. (1994). 24
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Table3. Comparison of the immunoreactive Anx-1 distribution ih control animals
and animals treated with methylprednisolone or the 21-aminosteroid, and the
occurrence of immunoreactive annexin-1
Structure Control Methyl- 21-amino- Literature
prednisolone steroid
Telencephalon
Caudate-putamen +4- +4- 4-4- nd
Cortex 4-+
layer + + +
layer 2 ++ ++ ++
layer 3, 4 + + +
layer 5 ++ ++
layer 6 + + +
Olfactory bulb 4- 4- + nd
Amygdala + 4- 4- ++
Corpus callosum nd
Fibres + + +
Oligodendroglia 0 0 0
Hippocampus
CA1 + ++ ++ ++
CA2 + ++ ++ ++
CA3 + +++ ++ ++
Dentate gyrus granular layer + 4-+ +4- 4-+
Fimbria hippocampi 0 0 0 nd
Septum + + + ++
Bed nucleus striae terminalis + + + nd
Diencephalon
Hypothalamus
Thalamus + ++ ++ ++
Epithalamus nd
habenular nucleus + +4- 4-+
Non-parenchymal tissue
Vascular wall + + + 4-
Meninges ++ ++ ++ 0
Choroid plexus + 4- + 0
Ventricular ependymocytes ++ +4- ++ +4-
The scores of subjective evaluations were ranked as follows: 0= no signal/cells labelled,
+ weak signal, ++ strong sigqal, +4-+ very strong signal, nd not determined.
aReferences: Strijbas etal. (1991) and Go etal. (1994).
10
Structures exhibiting the Anx-1
mRNA signal
The areas of the fore- and midbrain which
showed a hybridization signal of Anx-1 mRNA
are summarized in Table 2. They include the
following areas of the telencephalon: layers 2-6
of the cortex, the olfactory bulb, the nuclei of
the amygdala, in the hippocampus the pyrami-
dal and molecular layers of the CA1, CA2 and
CA3 area and the granular layer of the dentate
gyrus, furthermore in the septum and the
striatum. Scattered cells were labelled in the
hypothalamus, the thalamus and the epithala-
mus. In the cortex, especially layer 2 of the
pyriform and cingulate area showed a high
signal intensity (Fig. 2B). Along the fibre bun-
dles of the corpus callosum the oligodendoglia
were labelled (Fig. 2A).
No labelling was observed in layer 1 of the
cortex and the fimbria of the hippocampus, and
notably in the cells constituting the vascular
wall, the meninges, the ventricular ependyma,
and the choroid plexus (Fig. 2A).
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The Anx-1 mRNA in situ hybridization
signal in the various groups
The control animals showed labelling of struc-
tures shown in Table 2.
The methylprednisolone-treated animals
showed Anx-1 mRNA hybridization signals in
the same areas as the controls, but far more
intense, although the sections had been treated
in the same session. Especially the various
structures of the hippocampus and the habenu-
lar nucleus exhibited a strong increase of signal
intenstiy when compared with the controls
(Fig. 1). The areas in which Anx-1 mRNA
labelling was absent in the controls, such as the
cells of the meninges, the ependyma, the vas-
cular wall, and the choroid plexus also lacked
Anx-1 hybridization signals in the steroid-treated
animals.
Pretreatment with the 21-aminosteroid
U74389F gave similar results as pretreatment
with methylprednisolone. The only difference
was found in the CA3 area of the hippocampus
in which Anx-1 mRNA expression was less thanInduction ofannexin-1
FIG. 1. Photomicrographs demonstrating Anx-1 mRNA by ISH using antisense digoxigenin-labelled cRNA (A, C and E), and
immunoreactive Anx-1 (B, D and F) in the hippocampal CA3 area of untreated control (A and B), of methylprednisolone-
pretreated (C and D), and of 21-aminosteroid-pretreated rats (E and F).
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in the methylprednisolone-treated rats (Fig. 1C
and 1E). Again no signal was observed in the
cells of the meninges, the ependyma, the
vascular wall, and the choroid plexus.
Immunocytochemistry of Anx-1
protein
In the brains of the control rats, Anx-1 im-
munoreactivity was observed in layers 2 and 5
of the cerebral cortex, and to a lesser extent in
the other cortical layers; furthermore in the
basal ganglia, the amygdala, hippocampus, hy-
pothalamus and thalamus (Table 3). The distri-
bution of Anx-1 immunoreactivity was only
slightly different from that of Anx-1 mRNA on
the ISH: Anx-1 immunostaining of the neuronal
cells was most pronounced both in layers 2 and
5, whereas only layer 2 showed the most
abundant Anx-1 mRNA expression. In addition,
immunoreactive Anx-1 was found in small
varicose nerve fibres of neuronal cells, the
ventricular ependyma, the choroid plexus, the
meningeal cells and sporadically in cells of the
vascular wall (Figs 1B, 2C, 2D and 2E). Contrary
to the ISH, immunostaining was found in the
fibres but not in the oligodendroglia of the
corpus callosum.
Methylprednisolone or the 21-aminosteroid
pretreatment increased Anx-1 immunoreactivity
in other structures, notably the hippocampus,
the hypothalamus and thalamus (Fig. 1), but did
not change the Anx-1 immunostaining of cere-
bral cortex, basal ganglia, amydala, septum,
meninges, vascular wall, choroid plexus, and
ependyma.
FIG. 2. Photomicrographs of details of ISH and immunoreactive Anx-1 of methylprednisolone-pretreated rats. (A) ISH of the
choroid plexus, oligodendroglia in the corpus callosum, and part of the hippocampus. (B) ISH of the cortex, retrosplenial
area. Immunohistochemistry of: (C) the choroid plexus, (D) cortex, (E) detail of cortex; glia (g), cells of the vascular wall (v)
and neurones (n).
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was carried out for a shorter period on tissue Discussion
sections which had been attached to glass
Non-radioactive ISH with digoxigenin-labelled slides. Moreover, the presence of Anx-1 protein
probes as applied in the present study, is a rapid in the group of control animals is consistent
technique with reasonably high spatial resolu- with the finding of Anx-1 mRNA in the controls,
tion. The use of a PCR to incorporate a RNA- albeit in low, presumably resting levels of
polymerase promoter-region in the eDNA con- transcription. This resting state of Anx-1 mRNA
stitutes a simple way to produce a template for transcription may reflect hormonal influences
the RNA-transcription reaction and requires no under physiological conditions, such as the
cloning.
2 Labelling of the probe with dig- normal glucocorticoid secretion by the adrenals
oxigenin-ll-UTP also proved a simple and as governedbythe hypothalamo-pituitaryaxis.
effective procedure. The ISH protocol used in The only type of glial cells which could be
this study has evolved from a number of differ- recognized with reasonable certainty in the
ent protocols.13-16 present study, without requiring cell-type speci-
In the present study Anx-1 mRNA has pre- tic immunocytochemical markers were the oli-
dominantly been shown in neuronal cells with- godendroglia in the white matter. Astrocytes
in various structures of the brain. Notably, no have been shown to express Anx-1 mRNA
21 and
Anx-1 mRNA has been found in the capillary to possess glucocorticoid receptors, and may
endothelium and the choroid plexus. Our pre- therefore be assumed to be among the labelled
vious immunocytochemical studies have demon- cells in the cortex. In the hippocampus, on the
strated annexins in the choroid plexus of other hand, no cells with the morphological
control animals.
1 Also, Anx-1 protein has been features of astrocytes have been found to be
demonstrated in choroid plexus and in cellular labelled.
elements of some other circumventricular or- In the steroid-pretreated animals, there was
gans, such as the median eminence.17a8 The increased, transcription of Anx-1 mRNA in all
choroid plexus as well as the other circumven- structures of the brain, as in other tissue.22’23
tricular organs are notably devoid of a blood- Evidence of an increase of Anx-1 immunosta’in-
brain barrier. Therefore, the Anx-1 protein oh- ing, however, was only found in some struc-
served in the choroid plexus may well be of tures, notably the hippocampus, the
systemic origin, having entered because of the hypothalamus and thalamus. Another inconsis-
lack of a blood-brain barrier. This contention tency was the absence of Anx-1 in the oligoden-
seems now to be confirmed by the absence of droglia in spite of ISH evidence of Anx-1 mRNA.
Anx-1 mRNA in these structures as demon- It may be speculated that in these cases trans-
strated by ISH. lation of the Anx-1 protein has not followed the
In addition, Anx-1 protein could be demon- mRNA transcription, presumably impeded by
strated in the meninges, the ventricular ependy- influences yet to be clarified.
ma, and the vascular wall, whereas ISH showed Glucocorticoids can cross the blood-brain
no Anx-1 mRNA transcription. Since these barrier, and after entering the parenchymal cells
structures are located behind the blood-brain bind to the intracellular glucocorticosteroid
barrier, the protein may have originated by receptor. The receptor and its mRNA have been
diffusion possibly followed by preferential accu- demonstrated by immunohistochemistry to oc-
mulation from adjacent areas; diffusion of pro- cur in nuclei of neuronal and glial cells of the
teins is a well-known and aspecific process in central nervous system with a widespread, but
brain tissue.19 An alternative explanation would heterogeneous distribution.2425 On comparing
be the disparate turn-over rates of mRNA,
2 the distribution of Anx-1 mRNA with that of
which may explain subsequent rapid disappear- glucocorticoid receptors (Table 2), a correlation
ance of the mRNA. seems to be apparent. The recently introduced
Although in our previous study evidence of 21-aminosteroids have been claimed to exert
Anx-1 immunocytostaining has not been found their action by a direct membrane-protective
in the larger part of the brain of control animals, effect a,ainst oxidation by oxygen-derived free
in the present study Anx-1 immunostaining radicals,
6 lacking the glucocorticosteroid effect
occurred in quite a number of cerebral struc- on glucose metabolism; however, our results
tures. The differences are most probably attribu- indicate that they induce expression of annex-
table to the far greater sensitivity of the free- ins as well.
floating technique, by which in the present Although in the early 1980s the annexins
study the immunohistochemistry was carried have been discovered mainly in their role of
out overnight on 40 tzm sections, whereas in mediators of glucocorticosteroid anti-inflamma-
the previous study the immunohistochemistry tory action by their alleged inhibition of phos-
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pholipase A2mwith a similar effect on brain
oedema being the object of the present studym
other properties of the annexins have been
revealed in the meantime, including anticoag-
ulant activity (placental Anx-3 and Anx-4),
channel activity (Anx-7, Anx-5 and Anx-1),
trafficking of vesicles like endocytosis and
exocytosis and aggregation of synaptic vesicles
(Anx-7, Anx-2, Anx-3 and Anx-4), and involve-
ment in proliferation and differentiation pro-
cesses (Anx-1 and Anx-2).27 The recent
elucidation of the crystal structures of Anx-5
and Anx-12 has revived the discussion on their
role of channels, particularly in view of the
hexameric structure of Anx-12.28,29
In conclusion the present study has demon-
strated the presence of annexin-1 in the brain
as a result of local transcription of the Anx-1
mRNA, exhibiting an upregulation following
administration of a glucocorticosteroid as well
as a 21-aminosteroid. In view of the previously
demonstrated anti-inflammatory and anti-oede-
matous effects of these steroids, this upregula-
tion of annexin expression is presumably
involved in mediating these steroid actions on
phospholipase A2 activity in the arachidonic
acid cascade and eicosanoid formation. Besides,
a resting level of annexin expression has been
observed which presumably reflects physiologi-
cal conditions, in which their alleged other
functions such as those of channels or in vesicle
formation are relevant. It has also been demon-
strated by the absence of mRNA transcription,
that their occurrence in the choroid plexus can
be attributed to a lack of the blood-brain
barrier, and that in this respect annexins do not
differ from other proteins.
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